Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

Blood

Volumn 120, Issue 13, 2012, Pages 2581-2588

  Mateos, María Victoria ^a   Oriol, Albert ^b   Martínez López, Joaquín ^c   Gutiérrez, Norma ^a   Teruel, Ana Isabel ^d   De La Guía, Ana López ^e   López, Javier ^f   Bengoechea, Enrique ^g   Pérez, Montserrat ^h   Polo, Marta ⁱ   Palomera, Luis ^j   De Arriba, Felipe ^k   González, Yolanda ^l   Hernández, Jose Mariano ^m   Granell, Miquel ⁿ   Bello, José Luis ^o   Bargay, Joan ^p   Peñalver, Francisco Javier ^q   Ribera, José María ^b   Martín Mateos, María Luisa ^r   García Sanz, Ramón ^a   Lahuerta, Juan José ^c   Bladé, Joan ^s   San Miguel, Jesús F ^a   more..

^a CSIC   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h HOSPITAL VIRGEN DE LA CONCHA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL MORALES MESEGUER   (Spain)

^l HOSPITAL JOSEP TRUETA   (Spain)

^m HOSPITAL GENERAL DE SEGOVIA   (Spain)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^p Hospital Sont Llatzer   (Spain)

^q HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^r HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^s HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; ASTHENIA; CANCER PATIENT; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84866851061     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-427815     Document Type: Article

References (25)

1. Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127(2):159-164. (Pubitemid 39371808)
2. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107(4):1292-1298. (Pubitemid 43242361)
3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16(12):3832-3842.
4. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119(13):3003-3015.
5. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831. (Pubitemid 43363369)
6. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218. (Pubitemid 47516593)
7. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
8. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-3166.
9. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-1412.
10. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86(1):16-22.
11. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113(15):3435-3442.
12. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7-15.
13. Palumbo A, Delforge M, Catalano J, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients > = 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 622.
14. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-5109.
15. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 478.
16. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
17. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21(1):143-150. (Pubitemid 44921845)
18. Lopez-Corral L, Gutierrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17(7):1692-1700.
19. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
20. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 40.
21. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27(11):1788-1793.
22. Ludwig H, Adam Z, Tothova E, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010;95(9):1548-1554.
23. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025-3130.
24. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-1247.
25. Miguel JFS, Schlag R, Khuageva NK, et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 476.